The Optimal First-Line Therapy ofHelicobacter pyloriInfection in Year 2012
نویسندگان
چکیده
منابع مشابه
The Optimal First-Line Therapy of Helicobacter pylori Infection in Year 2012
This paper reviews the literature about first-line therapies for H. pylori infection in recent years. First-line therapies are facing a challenge because of increasing treatment failure due to elevated antibiotics resistance. Several new treatment strategies that recently emerged to overcome antibiotic resistance have been surveyed. Alternative first-line therapies include bismuth-containing qu...
متن کاملFirst Line Therapy in 2014
The choice of antiretroviral therapy for those naïve to therapy is vast, with over 30 drugs available for the treatment of HIV disease. Although international and national guidelines often give recommended preferred choices for commencement of therapy, it is important that treatment is always individualised. Therefore for the individual patient, it may be necessary to utilise treatments outside...
متن کاملFirst-line and second-line antiretroviral therapy.
January, 2004, administration of measles vaccine was recommended between 12 and 24 months of age, instead of between 12 and 15 months when children have the greatest risk of contracting measles. There is no established system to check vaccination status on entry to the school systems. Strong political and social desire has to be inspired, and vigorous educational campaigns for policy makers and...
متن کاملWhat Is the Optimal First Line Antiretroviral Therapy in Resource-Limited Settings?
Choosing an optimal first line antiretroviral therapy (ART) in resource-limited settings (RLS) involves a careful balancing act. On the one hand, we would want to ensure that patients receive the most efficacious therapy available. On the other hand, the most efficacious regimens may be too costly for countries afflicted by the dual burdens of very high HIV prevalence and of resource scarcity. ...
متن کاملOptimal First-Line Therapy for Previously Untreated Chronic Lymphocytic Leukemia: The Case for Kinase Inhibitors.
The traditional approach to therapy for previously untreated patients with chronic lymphocytic leukemia (CLL) has been chemoimmunotherapy programs (whether FCR [fludarabine, cyclophosphamide, rituximab], FR [fludarabine, rituximab], BR [bendamustine, rituximab], PCR [pentostatin, cyclophosphamide, rituximab], other. These combination treatments have led to increased rates of clinical remission,...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Gastroenterology Research and Practice
سال: 2012
ISSN: 1687-6121,1687-630X
DOI: 10.1155/2012/168361